



Yezo'otogirins A–C, new tricyclic terpenoids from *Hypericum yezoense*

Naonobu Tanaka, Yuka Kakuguchi, Haruaki Ishiyama, Takaaki Kubota, Jun'ichi Kobayashi *

Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

ARTICLE INFO

Article history:

Received 11 May 2009

Revised 2 June 2009

Accepted 5 June 2009

Available online 9 June 2009


ABSTRACT

Three new tricyclic terpenoids, yezo'otogirins A–C (**1–3**), were isolated from aerial parts of *Hypericum yezoense*. The structures including absolute stereochemistry of **1–3** were elucidated from the spectroscopic data and conformational analysis.

© 2009 Elsevier Ltd. All rights reserved.

The genus *Hypericum* (family Clusiaceae) is known to be a traditional medicine for the treatment of burns, bruises, swelling, inflammation, and anxiety as well as bacterial and viral infections.¹ In our continuing search for structurally interesting compounds from *Hypericum* spp.,² three new tricyclic terpenoids, yezo'otogirins A–C (**1–3**), were isolated from *H. yezoense*. In this Letter, we describe the isolation and structure elucidation of **1–3**.

The aerial parts of *H. yezoense* were extracted with MeOH, and the extracts were partitioned with *n*-hexane and H₂O. *n*-Hexane-soluble portions were subjected to a silica gel column (CHCl₃/MeOH) and a Sephadex LH-20 column (EtOH) chromatographies, and then purified by C₁₈ HPLC (MeOH/H₂O) to yield yezo'otogirins A (**1**, 0.0003%), B (**2**, 0.0002%), and C (**3**, 0.00003%) together with a known hyperforin analogue (**4**).³



Yezo'otogirin A (**1**)⁴ showed the molecular ion peak at m/z 398 (M)⁺ in the EIMS, and the HREIMS analysis revealed the molecular formula to be C₂₇H₄₂O₂ (m/z 398.3184 [M]⁺, Δ –0.1 mmu). The IR absorption at 1696 cm^{–1} implied the presence of carbonyl func-

tionality. ¹H and ¹³C NMR data (Table 1) of **1** indicated the presence of one 2-methylpropanoyl group, two prenyl groups, three sp² quaternary carbons, three sp³ quaternary carbons, two sp³ methines, three sp³ methylenes, and three tertiary methyl groups. Analysis of the ¹H–¹H COSY spectrum revealed connections of C-8–C-9, C-8–C-10, C-23–C-24, C-12–C-14, C-4–C-5, C-4–C-18, and C-18–C-19 (Fig. 1). HMBC cross-peaks of H₂-23 to C-1, C-5, and C-6 suggested that C-1, C-5, and C-23 were connected to C-6. Connections among C-14, C-16, and C-17 through C-15 were implied by HMBC cross-peaks of H₃-17 to C-14, C-15, and C-16, while connections among C-2, C-4, C-11, and C-12 via C-3 were indicated by HMBC cross-peaks of H₃-11 to C-2, C-3, C-4, and C-12. HMBC correlations for H-14 to C-1, C-2, and C-7 suggested that C-2 was connected to C-1, C-7, and C-14. The presence of an ether linkage between C-1 and C-15 was deduced from the chemical shift of C-15 (δ_C 83.3) and unsaturated degree of **1**. Thus, the gross structure of yezo'otogirin A was elucidated to be **1**.

The relative stereochemistry of **1** is deduced from NOESY correlations as shown in Figure 2. The NOESY cross-peaks of H-14/H-12 β , H-14/H-13 β , H-14/H₃-16, H₃-11/H-12 β , and H₃-11/H-18 indicated that these protons were β -oriented, while the α -orientation of H-4 was revealed by the correlation for H-4 to H-5 α . In addition, the NOESY cross-peaks of H-8/H-5 β and H-8/H₃-11 suggested that the 2-methylpropanoyl group was β -oriented. Thus, the relative stereochemistry of **1** is assigned as shown in Figure 2.

The HRESIMS of yezo'otogirin B (**2**)⁵ revealed the molecular formula to be C₂₈H₄₄O₂ (m/z 435.3253 [M+Na]⁺, Δ +1.4 mmu), which was larger by 14 mass units as compared with that of yezo'otogirin A (**1**). ¹H and ¹³C NMR data of **2** were similar to those of **1**, except for the presence of signals due to a 2-methylbutanoyl group in place of those of a 2-methylpropanoyl group in **1**. The HMBC correlation for H-14 to C-7 indicated that the 2-methylbutanoyl group was attached to C-2 (Fig. 3). The NOESY spectrum of **2** showed correlations similar to that of **1** (Fig. 4). The relative stereochemistry of C-8 was deduced from NOESY cross-peaks of H-8/H-5 β , H-8/H₃-11, and H₃-9/H₃-11. Thus, the structure and relative stereochemistry of yezo'otogirin B were elucidated to be **2**.

* Corresponding author. Tel.: +81 11 706 3239; fax: +81 11 706 4989.
E-mail address: jkobay@pharm.hokudai.ac.jp (J. Kobayashi).

Table 1
 ^1H and ^{13}C NMR data for yezo'otogirins A–C (1–3) in CDCl_3

Position	1		2		3	
	^{13}C	$^1\text{H}^a$	^{13}C	$^1\text{H}^a$	^{13}C	$^1\text{H}^a$
1	149.0	—	148.8	—	149.3	—
2	73.6	—	73.6	—	73.6	—
3	48.6	—	48.6	—	48.5	—
4	47.5	1.15 (1H, m)	47.5	1.15 (1H, m)	47.0	1.22 (1H, m)
5	29.7	1.93 (1H, dd, $J = 14.9, 3.2$) 1.80 (1H, dd, $J = 14.9, 10.9$)	29.7	1.93 (1H, dd, $J = 15.5, 3.1$) 1.81 (1H, dd, $J = 15.5, 10.8$)	32.8	1.95 (1H, dd, $J = 15.3, 11.4$) 1.86 (1H, dd, $J = 15.3, 3.0$)
6	111.4	—	111.6	—	107.5	—
7	217.4	—	216.1	—	217.4	—
8	37.8	2.99 (1H, sept, $J = 6.9$)	44.5	2.74 (1H, m)	37.9	2.96 (1H, sept, $J = 6.6$)
9	18.3 ^b	1.02 (3H, d, $J = 6.9$) ^c	14.2	1.00 (3H, d, $J = 6.9$)	18.3 ^d	1.01 (3H, d, $J = 6.6$) ^e
10	21.6 ^b	1.01 (3H, d, $J = 6.9$) ^c	27.5	1.70, 1.03 (each 1H, m)	21.5 ^d	1.01 (3H, d, $J = 6.6$) ^e
11	19.5	0.73 (3H, s)	19.7	0.74 (3H, s)	19.6	0.75 (3H, s)
12	41.3	1.74, 1.34 (each 1H, m)	41.2	1.74, 1.34 (each 1H, m)	41.5	1.75, 1.46 (each 1H, m)
13	25.5	1.53 (2H, m)	25.4	1.53 (2H, m)	25.4	1.54 (2H, m)
14	54.9	3.19 (1H, t, $J = 9.7$)	54.7	3.20 (1H, t, $J = 9.8$)	54.9	3.18 (1H, t, $J = 9.6$)
15	83.3	—	83.4	—	83.4	—
16	29.4	1.13 (3H, s)	29.5	1.14 (3H, s)	29.4	1.14 (3H, s)
17	25.3	1.18 (3H, s)	25.3	1.18 (3H, s)	25.4	1.18 (3H, s)
18	29.5	1.89, 1.82 (each 1H, m)	29.5	1.88, 1.83 (each 1H, m)	29.6	1.93, 1.81 (each 1H, m)
19	124.3	5.07 (1H, t, $J = 7.5$)	124.3	5.07 (1H, m)	124.2	5.11 (1H, t, $J = 6.9$)
20	132.0	—	132.2	—	132.3	—
21	25.9	1.72 (3H, s)	25.7	1.71 (3H, s)	25.8	1.72 (3H, s)
22	17.8	1.59 (3H, s)	17.8	1.60 (3H, s)	17.8	1.60 (3H, s)
23	28.8	2.82, 2.79 (each 1H, dd, $J = 14.2, 7.3$)	28.9	2.82, 2.79 (each 1H, dd, $J = 14.8, 6.8$)	16.3	1.70 (3H, s)
24	121.8	5.06 (1H, t, $J = 7.3$)	122.0	5.07 (1H, m)	—	—
25	132.2	—	131.9	—	—	—
26	25.7	1.70 (3H, s)	25.9	1.70 (3H, s)	—	—
27	17.8	1.65 (3H, s)	17.7	1.65 (3H, s)	—	—
28	—	—	11.6	0.86 (3H, t, $J = 7.2$)	—	—

^a Coupling constants are given (J , Hz) in parentheses.
^{b–e} Signals may be exchangeable.




Figure 1. Selected 2D NMR correlations for yezo'otogirin A (1).




Figure 3. Selected 2D NMR correlations for yezo'otogirin B (2).




Figure 2. Selected NOESY correlations and relative stereochemistry for yezo'otogirin A (1) (C-19–C-27 were not shown).




Figure 4. Selected NOESY correlations and relative stereochemistry for yezo'otogirin B (2) (C-19–C-27 were not shown).

The molecular formula of yezo'otogirin C (**3**),⁶ C₂₃H₃₆O₂, was established by the HRESIMS, which was smaller by 54 mass units as compared with that of yezo'otogirin A (**1**). Except for signals of an alkyl side chain at C-6, ¹H and ¹³C NMR data of yezo'otogirin C (**3**) were similar to those of **1** (Table 1). HMBC correlations for H₃-23 to C-1, C-5, and C-6 indicated that a methyl group was attached to C-6 (Fig. 5). The relative stereochemistry of **3** was elucidated to be the same as that of **1** from NOESY correlations for **3** (Fig. 6), which were similar to those observed for **1**. Thus, the structure of yezo'otogirin C was assigned as **3**.

Absolute stereochemistry of yezo'otogirin A (**1**) was elucidated on the basis of the pattern of CD spectrum of **1**. The most stable conformer of **1**, which was obtained by the conformational analysis




Figure 5. Selected 2D NMR correlations for yezo'otogirin C (**3**).




Figure 6. Selected NOESY correlations and relative stereochemistry for yezo'otogirin C (**3**) (C-19–C-22 were not shown).




Figure 7. The most stable conformer of yezo'otogirin A (**1**) (C-18–C-27 and hydrogen atoms are not shown).





Figure 8. CD (A) and UV (B) spectra of yezo'otogirin A (**1**) in MeOH.



Scheme 1. Plausible biogenetic path of yezo'otogirin A (**1**).

(MacroModel, MM3 force-field), is shown in Figure 7. This conformer agreed with that estimated by NOESY analysis (Fig. 2). It was reported that mixing of the olefinic $\pi \rightarrow \pi^*$ transition with carbonyl $n \rightarrow \pi^*$ band of β, γ -unsaturated ketones results in the chirality of the β, γ -heterodiene π -system dominating the sign of the $n \rightarrow \pi^*$ CD band.⁷ Negative Cotton effect at 308 nm ($\Delta\epsilon$ –8.3) in the CD spectrum for **1** (Fig. 8) suggested the chirality of the β, γ -heterodiene π -system (O-7–C-7–C-2–C-1–C-6) as shown in Figure 7. Thus, the absolute configurations at C-2, C-3, C-4, and C-14 of yezo'otogirin A (**1**) were assigned to be *S*, *R*, *S*, and *R*, respectively. Absolute configurations of yezo'otogirins B (**2**) and C (**3**) were also assigned to be 2*S*, 3*R*, 4*S*, 8*S*, and 14*R* for **2**, 2*S*, 3*R*, 4*S*, and 14*R* for **3**, respectively, due to negative Cotton effects at 308 nm ($\Delta\epsilon$ –6.6 and –2.4, respectively).

Yezo'otogirins A–C (**1–3**) are new tricyclic terpenoids with a rare ring system from natural sources. A plausible biogenetic path for yezo'otogirin A (**1**) is proposed as shown in Scheme 1. Yezo'otogirin A (**1**) could be derived from a known hyperforin analogue (**4**),³ by intramolecular cyclization. Yezo'otogirins A–C (**1–3**) did not show cytotoxicity against L1210 murine leukemia (IC₅₀ >10 $\mu\text{g}/\text{mL}$) in vitro.

Acknowledgments

We thank N. Yoshida, Health Sciences University of Hokkaido, for collection and botanical identification of the plant, S. Oka and A. Tokumitsu Center for Instrumental Analysis, Hokkaido University, for measurements of HRESIMS and HREIMS. This work was partly supported by a grant from the Kuribayashi Foundation and

a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References and notes

- (a) Nahrstedt, A.; Butterweck, V. *Pharmacopsychiatry* **1997**, *30*, 129–134; (b) Dostalek, M.; Pistovcakova, J.; Jurica, J.; Tomandl, J.; Linhart, I.; Sulcava, A.; Hadasova, E. *Life Sci.* **2005**, *78*, 239–244; (c) Medina, M. A.; Martínez-Proveda, B.; Amores-Sánchez, M. I.; Quesada, A. R. *Life Sci.* **2006**, *79*, 105–111; (d) Beerhues, L. *Phytochemistry* **2006**, *67*, 2201–2207.
- Tanaka, N.; Kubota, T.; Ishiyama, H.; Kashiwada, Y.; Takaishi, Y.; Ito, J.; Mikami, Y.; Shiro, M.; Kobayashi, J. *Heterocycles* **2009**, *79*, 917–924.
- Shan, M. D.; Hu, L. H.; Chen, Z. L. *J. Nat. Prod.* **2001**, *64*, 127–130.
- Yezo'otogirin A (**1**) colorless oil; $[\alpha]_D^{23}$ -168.2 (c 0.25 CHCl₃); IR (KBr) ν_{\max} 2931, 1696, 1450, 1381, and 1086 cm⁻¹; ¹H and ¹³C NMR data (Table 1); EIMS m/z 398 (M)⁺; HREIMS: m/z 398.3184 (M)⁺ (calcd for C₂₇H₄₂O₂, 398.3185); CD (MeOH) $\Delta\epsilon$ (nm) -8.3 (308) and $+4.1$ (257).
- Yezo'otogirin B (**2**) colorless oil; $[\alpha]_D^{23}$ -165.7 (c 0.15 CHCl₃); IR (KBr) ν_{\max} 2930, 1694, 1457, 1381, and 1090 cm⁻¹; ¹H and ¹³C NMR data (Table 1); ESIMS m/z 435 (M+Na)⁺; HRESIMS: m/z 435.3253 (M+Na)⁺ (calcd for C₂₈H₄₄O₂Na, 435.3239); CD (MeOH) $\Delta\epsilon$ (nm) -6.6 (308) and $+4.0$ (268).
- Yezo'otogirin C (**3**) Colorless oil; $[\alpha]_D^{23}$ -57.2 (c 0.05 CHCl₃); IR (KBr) ν_{\max} 2920, 1697, 1465, 1381, and 1105 cm⁻¹; ¹H and ¹³C NMR data (Table 1); ESIMS m/z 367 (M+Na)⁺; HRESIMS: m/z 367.2603 (M+Na)⁺ (calcd for C₂₃H₃₆O₂Na, 367.2613); CD (MeOH) $\Delta\epsilon$ (nm) -2.4 (308) and $+1.4$ (255).
- (a) Su, J.; Zhong, Y.; Shi, K.; Cheng, Q.; Snyder, J. K.; Hu, S.; Huang, Y. *J. Org. Chem.* **1991**, *56*, 2337–2344; (b) Schippers, P. H.; Dekkers, H. P. J. *M. J. Am. Chem. Soc.* **1983**, *105*, 79–84.